Opinion - (2025) Volume 9, Issue 5
Received: 01-Oct-2025, Manuscript No. jid-26-188346;
Editor assigned: 03-Oct-2025, Pre QC No. P-188346;
Reviewed: 17-Oct-2025, QC No. Q-188346;
Revised: 22-Oct-2025, Manuscript No. R-188346;
Published:
29-Oct-2025
, DOI: 10.37421/2684-4559.2025.9.349
Citation: Fujimoto, Keiko. "Relapsing P. vivax Malaria: Southeast Asia's Elimination Challenge." Clin Infect Dis 13 (2025):349.
Copyright: © 2025 Fujimoto K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Plasmodium vivax malaria presents a significant challenge to global malaria elimination efforts due to its unique relapse pattern, primarily driven by dormant liver-stage parasites known as hypnozoites. Southeast Asia, a region with a high burden of P. vivax infections, faces particular difficulties in eradicating the disease because of the persistent threat of these relapses, which can occur months or even years after the initial infection and contribute to ongoing transmission. This review synthesizes current research to provide a comprehensive overview of the epidemiology, genetic underpinnings, and control strategies for P. vivax relapses in this endemic region. The epidemiology of Plasmodium vivax relapses in Southeast Asian endemic regions is a critical area of study, highlighting the persistent hurdle these relapses pose to malaria elimination. The complex biology of hypnozoites, the dormant liver-stage parasites responsible for these relapses, and their impact on transmission dynamics and control program effectiveness are emphasized, alongside the need for improved diagnostics and radical treatment strategies to address the ongoing threat of P. vivax [1].
Understanding the genetic basis of Plasmodium vivax relapse is paramount for developing effective interventions against this challenging aspect of malaria. Research exploring variations in genes related to hypnozoite activation and dormancy, and linking them to observed relapse patterns in Southeast Asian populations, suggests that genetic factors significantly influence individual susceptibility to relapse, thereby informing more targeted control efforts [2].
Longitudinal and spatial epidemiological studies are vital for mapping and understanding the patterns of Plasmodium vivax relapses. Research examining long-term trends and spatial distribution in highly endemic areas of Vietnam, utilizing extensive historical data to identify hotspots and temporal patterns, reveals that relapses substantially contribute to the overall malaria burden and impede elimination goals, underscoring the persistent challenge posed by hypnozoite reservoirs [3].
The efficacy and safety of primaquine, the cornerstone drug for the radical cure of P. vivax, are under continuous investigation to optimize its use in malaria elimination. Clinical trials assessing treatment outcomes and adherence in regions like Cambodia highlight challenges associated with G6PD deficiency and potential adverse events, which can limit its widespread application in relapse prevention, thus indicating a need for safer and more effective radical treatment options [4].
Current knowledge on the drivers of Plasmodium vivax relapse in Southeast Asia, encompassing parasite biology, host immunity, and environmental influences, is being synthesized to inform elimination strategies. The emphasis is on the necessity for successful elimination efforts to comprehensively address the often-underestimated hypnozoite reservoir, advocating for integrated approaches that combine surveillance, diagnosis, and treatment [5].
The role of asymptomatic Plasmodium vivax infections and low-level parasitemia in sustaining transmission and contributing to relapses is a growing area of concern. Studies in Thailand reveal that individuals harboring dormant hypnozoites may not exhibit acute symptoms, acting as a hidden reservoir for infection and subsequent relapse, thereby highlighting the critical importance of sensitive diagnostic tools [6].
Novel approaches for the radical cure of Plasmodium vivax are actively being pursued, with a focus on the development and evaluation of new drugs specifically targeting hypnozoites. The review of potential therapeutic candidates, their mechanisms of action, and their promise in overcoming the limitations of current treatments like primaquine signifies progress in the quest for a safer and more effective radical cure [7].
The impact of population movement and migration on the persistence of Plasmodium vivax relapses in border regions of Southeast Asia is a complex epidemiological factor that complicates elimination efforts. Studies highlight how mobile populations can reintroduce the parasite and its dormant forms into areas that were previously malaria-free, necessitating integrated cross-border malaria control strategies [8].
Diagnostic challenges in identifying and quantifying Plasmodium vivax hypnozoites, the primary source of relapses, remain a significant obstacle. A review of existing diagnostic techniques and their limitations in detecting these dormant liver stages emphasizes the urgent requirement for sensitive and specific diagnostics that can effectively guide radical treatment [9].
Finally, the evaluation of newer drugs for radical cure, such as tafenoquine, in real-world settings is providing valuable insights into their effectiveness and convenience compared to older treatments. Studies in Laos comparing tafenoquine to primaquine suggest its potential as a more convenient option for relapse prevention, although concerns regarding G6PD deficiency screening persist [10].
The epidemiology of Plasmodium vivax relapses in Southeast Asian endemic regions presents a formidable obstacle to malaria elimination, largely due to the complex biology of hypnozoites, the dormant liver-stage parasites responsible for these recurrent infections. These relapses significantly impact transmission dynamics and diminish the effectiveness of current control programs, underscoring the critical need for enhanced diagnostic capabilities and more effective radical treatment strategies to combat the persistent threat posed by P. vivax [1].
Understanding the genetic underpinnings of Plasmodium vivax relapse is a crucial step towards developing targeted and effective interventions. Investigations into genetic variations associated with hypnozoite activation and dormancy, linked to observed relapse patterns in Southeast Asian populations, indicate that individual susceptibility to relapse is influenced by genetic factors, paving the way for more precise control strategies [2].
Longitudinal and spatial epidemiological research is essential for characterizing the patterns of Plasmodium vivax relapses and identifying areas of high risk. Studies that analyze long-term trends and geographical distributions in highly endemic regions, such as Vietnam, demonstrate that relapses contribute substantially to the overall malaria burden and hinder elimination efforts by perpetuating the hypnozoite reservoir [3].
The efficacy and safety of primaquine, the current standard treatment for radical cure of P. vivax, continue to be evaluated in various settings. Clinical trials conducted in Cambodia have illuminated challenges related to primaquine use, including issues with G6PD deficiency and potential adverse reactions, which can limit its widespread application for preventing relapses and highlight the need for alternative radical treatment options [4].
Synthesizing current knowledge on the drivers of Plasmodium vivax relapse in Southeast Asia involves considering a range of factors, from parasite biology and host immunity to environmental influences. This comprehensive review emphasizes that successful elimination strategies must address the hypnozoite reservoir, which is often underestimated, advocating for integrated approaches that combine surveillance, diagnosis, and treatment [5].
The contribution of asymptomatic Plasmodium vivax infections and low-level parasitemia to sustained transmission and the occurrence of relapses is a critical aspect of malaria epidemiology. Research in Thailand has shown that individuals carrying dormant hypnozoites may not exhibit overt symptoms, acting as a silent source of infection and relapse, thus emphasizing the importance of employing sensitive diagnostic tools [6].
Advancements in the quest for a radical cure for Plasmodium vivax are being driven by research into novel therapeutic targets and drug candidates. Studies investigating new drugs designed to target hypnozoites are reviewing the pipeline of potential treatments, discussing their mechanisms of action, and assessing their capacity to overcome the limitations associated with existing therapies like primaquine [7].
The influence of population movement and migration on the persistence of Plasmodium vivax relapses, particularly in border regions of Southeast Asia, presents a complex challenge to malaria control. It is recognized that mobile populations can reintroduce the parasite and its dormant forms into areas that were previously free of malaria, complicating eradication efforts and necessitating coordinated cross-border control strategies [8].
The detection and quantification of Plasmodium vivax hypnozoites, which are the origin of relapses, are hindered by significant diagnostic challenges. A review of current diagnostic techniques reveals limitations in accurately detecting these dormant liver-stage parasites, underscoring the urgent need for highly sensitive and specific diagnostic tools capable of guiding effective radical treatment [9].
Real-world evaluations of newer drugs for radical cure, such as tafenoquine, are providing crucial data on their effectiveness and potential advantages over existing treatments. Studies in Laos examining the use of tafenoquine for radical cure of P. vivax have suggested it as a more convenient option for relapse prevention compared to primaquine, although the necessity of G6PD deficiency screening remains a key consideration [10].
This collection of research focuses on Plasmodium vivax malaria relapses in Southeast Asia, a major impediment to elimination efforts. The studies highlight the critical role of dormant hypnozoites, genetic factors influencing relapse susceptibility, and the epidemiological patterns of recurrence. Challenges in radical cure, particularly with primaquine due to G6PD deficiency, are discussed, alongside the development of new drugs like tafenoquine. The impact of asymptomatic infections, population movement, and the need for improved diagnostics for hypnozoites are also emphasized. Integrated control strategies, including surveillance, diagnosis, and effective treatment, are crucial for addressing the persistent threat of P. vivax relapses and achieving malaria elimination.
Clinical Infectious Diseases: Open Access received 1149 citations as per Google Scholar report
